Why the Cynata Therapeutics share price is up 10% today

Here’s why the Cynata Therapeutics Ltd (ASX: CYP) share price has jumped 9.8% today

| More on:
health medical

The Cynata Therapeutics Ltd (ASX: CYP) share price has jumped 9.8% after opening today, with CYP shares trading at $1.11 at the time of writing. Cynata shares had closed at $1.02 yesterday before opening at $1.10 this morning and moving higher still after open.

Cynata Therapeutics is a Australian stem cell and regenerative medicine company. After today’s moves it is valued at approximately $115 million.

Why have Cynata shares moved?

Today’s gains can be attributed to the company releasing some positive data on the preclinical drug trial results of its Cymerus treatment. Cynata hopes Cymerus will be used in the effective treatment of sepsis (sometimes called ‘blood poisoning’), a life-threatening disease that arises from the body’s response to harm or infection. The company noted that sepsis is “a major medical challenge and the most common cause of death in hospital intensive care units.”

The company noted that in its trials, Cymerus mesenchymal stem cells successfully increased blood oxygen levels, improved lung health and decreased inflammation. The trials were co-funded by and conducted in partnership with the Royal College of Surgeons in Ireland.

Cynata’s Chief Operating Officer Dr Kilian Kelly described the trial results as “highly encouraging” and stated: 

We believe the data can support progression to a clinical trial in patients with sepsis. These latest results build on our broad preclinical database across a range of commercial opportunities, including asthma, heart disease and diabetes complications.

Cynata shares have fallen steeply since reaching their 52-week high back in late July of this year. Even after today’s share price moves, CYP shares are still trading toward the lower end of the company’s 52-week range ($0.94–1.87) and just shy of its year-to-date low.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News